drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00651 | DB09080 | 746 | 144 | [
"DDInter613",
"DDInter1331"
] | Dyphylline | Olodaterol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
746,
24,
144
]
],
[
[
746,
25,
1592
],
[
1592,
24,
144
]
],
[
[
746,
24,
455
],
[
455,
24,
144
]
],
[
[
746,
23,
22
],
[
22,
24,... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nebivolol"
],
[
"Nebivolol",... | Dyphylline may lead to a major life threatening interaction when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline may lead to a major life threatening interaction when taken with Betaxolol and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dyphylline may lead to a major life threatening interaction when taken with Carvedilol and Carvedilol may lead to a major life threatening interaction when taken with Olodaterol
Dyphylline may lead to a major life threatening interaction when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Olodaterol
Dyphylline may lead to a major life threatening interaction when taken with Nebivolol and Nebivolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol |
DB01168 | DB01404 | 1,053 | 757 | [
"DDInter1526",
"DDInter820"
] | Procarbazine | Ginseng | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1053,
24,
757
]
],
[
[
1053,
62,
126
],
[
126,
24,
757
]
],
[
[
1053,
21,
29024
],
[
29024,
60,
245
],
[
245,
24,
757
]
],
[
[
1053,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Procarbazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
... | Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Procarbazine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Ginseng |
DB00852 | DB01200 | 1,445 | 469 | [
"DDInter1545",
"DDInter243"
] | Pseudoephedrine | Bromocriptine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above. | Moderate | 1 | [
[
[
1445,
24,
469
]
],
[
[
1445,
64,
1131
],
[
1131,
1,
469
]
],
[
[
1445,
25,
628
],
[
628,
1,
469
]
],
[
[
1445,
6,
5372
],
[
5372,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Pseudoephedrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methysergide"
],
[
... | Pseudoephedrine may lead to a major life threatening interaction when taken with Methysergide and Methysergide (Compound) resembles Bromocriptine (Compound)
Pseudoephedrine may lead to a major life threatening interaction when taken with Ergometrine and Ergometrine (Compound) resembles Bromocriptine (Compound)
Pseudoephedrine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Bromocriptine (Compound)
Pseudoephedrine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Pseudoephedrine (Compound) resembles Phenylpropanolamine (Compound) and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may lead to a major life threatening interaction when taken with Bromocriptine
Pseudoephedrine may lead to a major life threatening interaction when taken with Methysergide and Methysergide (Compound) resembles Ergotamine (Compound) and Ergotamine (Compound) resembles Bromocriptine (Compound)
Pseudoephedrine may lead to a major life threatening interaction when taken with Ergometrine and Ergometrine (Compound) resembles Methysergide (Compound) and Methysergide (Compound) resembles Bromocriptine (Compound)
Pseudoephedrine may lead to a major life threatening interaction when taken with Methylergometrine and Methylergometrine (Compound) resembles Methysergide (Compound) and Methysergide (Compound) resembles Bromocriptine (Compound) |
DB01155 | DB01268 | 872 | 1,151 | [
"DDInter813",
"DDInter1731"
] | Gemifloxacin | Sunitinib | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
872,
24,
1151
]
],
[
[
872,
21,
29662
],
[
29662,
60,
1151
]
],
[
[
872,
62,
112
],
[
112,
23,
1151
]
],
[
[
872,
63,
1148
],
[
1148,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Candida infection"
],
[
"Candida infection",
"{u} (S... | Gemifloxacin (Compound) causes Candida infection (Side Effect) and Candida infection (Side Effect) is caused by Sunitinib (Compound)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin may lead to a major life threatening interaction when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin may lead to a major life threatening interaction when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Gemifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB08896 | DB15328 | 292 | 829 | [
"DDInter1576",
"DDInter1896"
] | Regorafenib | Ubrogepant | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Ubrogepant was approved by Health Canada on November 10, 2022. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition. | Moderate | 1 | [
[
[
292,
24,
829
]
],
[
[
292,
25,
1468
],
[
1468,
24,
829
]
],
[
[
292,
64,
578
],
[
578,
24,
829
]
],
[
[
292,
24,
26
],
[
26,
24,... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib... | Regorafenib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ubrogepant
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Ubrogepant
Regorafenib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant |
DB00427 | DB01105 | 1,233 | 222 | [
"DDInter1879",
"DDInter1665"
] | Triprolidine | Sibutramine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Moderate | 1 | [
[
[
1233,
24,
222
]
],
[
[
1233,
18,
7359
],
[
7359,
57,
222
]
],
[
[
1233,
24,
1563
],
[
1563,
24,
222
]
],
[
[
1233,
24,
733
],
[
733,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Triprolidine",
"{u} (Compound) downregulates {v} (Gene)",
"TXNDC9"
],
[
"TXNDC9",
"{u} (Gene) is downregulate... | Triprolidine (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Sibutramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine and Eslicarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Triprolidine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may lead to a major life threatening interaction when taken with Sibutramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may lead to a major life threatening interaction when taken with Sibutramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Sibutramine
Triprolidine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Sibutramine |
DB00536 | DB08826 | 1,225 | 1,292 | [
"DDInter848",
"DDInter489"
] | Guanidine | Deferiprone | A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011. | Major | 2 | [
[
[
1225,
25,
1292
]
],
[
[
1225,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
1225,
24,
4
],
[
4,
25,
1292
]
],
[
[
1225,
64,
1064
],
[
1064,
... | [
[
[
"Guanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Guanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compo... | Guanidine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Guanidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Deferiprone
Guanidine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Deferiprone
Guanidine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may lead to a major life threatening interaction when taken with Deferiprone
Guanidine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone
Guanidine (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Azacitidine (Compound) and Azacitidine may lead to a major life threatening interaction when taken with Deferiprone
Guanidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Deferiprone (Compound)
Guanidine may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Deferiprone (Compound)
Guanidine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone |
DB04837 | DB14575 | 649 | 733 | [
"DDInter407",
"DDInter674"
] | Clofedanol | Eslicarbazepine | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
649,
24,
733
]
],
[
[
649,
63,
1264
],
[
1264,
24,
733
]
],
[
[
649,
24,
1609
],
[
1609,
24,
733
]
],
[
[
649,
1,
820
],
[
820,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol (Compound) resembles Carbinoxamine (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol (Compound) resembles Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine |
DB00242 | DB11986 | 1,064 | 484 | [
"DDInter392",
"DDInter648"
] | Cladribine | Entrectinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
1064,
24,
484
]
],
[
[
1064,
24,
466
],
[
466,
62,
484
]
],
[
[
1064,
24,
1197
],
[
1197,
24,
484
]
],
[
[
1064,
25,
510
],
[
510,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may lead to a major life threatening interaction when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine (Compound) resembles Adenosine (Compound) and Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Cladribine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Entrectinib |
DB00476 | DB06779 | 109 | 365 | [
"DDInter608",
"DDInter470"
] | Duloxetine | Dalteparin | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Moderate | 1 | [
[
[
109,
24,
365
]
],
[
[
109,
63,
305
],
[
305,
24,
365
]
],
[
[
109,
25,
1039
],
[
1039,
24,
365
]
],
[
[
109,
40,
758
],
[
758,
2... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia co... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Duloxetine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Duloxetine (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Dalteparin
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Dalteparin
Duloxetine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Dalteparin
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Duloxetine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin |
DB00731 | DB06335 | 1,144 | 761 | [
"DDInter1269",
"DDInter1646"
] | Nateglinide | Saxagliptin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1144,
24,
761
]
],
[
[
1144,
6,
7524
],
[
7524,
45,
761
]
],
[
[
1144,
21,
28966
],
[
28966,
60,
761
]
],
[
[
1144,
62,
1103
],
[
1103... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound... | Nateglinide (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Saxagliptin (Compound)
Nateglinide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Saxagliptin (Compound)
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Nateglinide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Nateglinide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Nateglinide (Compound) resembles Lisinopril (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin |
DB01276 | DB14115 | 123 | 1,312 | [
"DDInter706",
"DDInter868"
] | Exenatide | Human botulinum neurotoxin A/B immune globulin | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding difficulties) which may progress to more serious symptoms such as respiratory arrest and flaccid paralysis.[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003 and has since been used to treat more than 2100 cases of infant botulism. It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program and comprises IgG antibodies derived from pooled adult plasma from persons immunized with recombinant botulinum vaccine who have high titers of neutralizing antibodies against botulinum toxin. | Moderate | 1 | [
[
[
123,
24,
1312
]
],
[
[
123,
63,
1132
],
[
1132,
25,
1312
]
],
[
[
123,
63,
1132
],
[
1132,
35,
416
],
[
416,
25,
1312
]
],
[
[
123,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Gentamicin (Compound) and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Polymyxin B and Polymyxin B may lead to a major life threatening interaction when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Human botulinum neurotoxin A/B immune globulin |
DB06441 | DB08918 | 936 | 41 | [
"DDInter283",
"DDInter1059"
] | Cangrelor | Levomilnacipran | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
936,
24,
41
]
],
[
[
936,
63,
901
],
[
901,
40,
41
]
],
[
[
936,
25,
498
],
[
498,
63,
41
]
],
[
[
936,
64,
330
],
[
330,
24,
... | [
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Cangrelor may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Cangrelor may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Cangrelor may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound) and Meperidine (Compound) resembles Levomilnacipran (Compound)
Cangrelor may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Cangrelor may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound) |
DB00544 | DB14783 | 970 | 287 | [
"DDInter757",
"DDInter574"
] | Fluorouracil | Diroximel fumarate | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
970,
24,
287
]
],
[
[
970,
24,
384
],
[
384,
24,
287
]
],
[
[
970,
63,
599
],
[
599,
24,
287
]
],
[
[
970,
23,
147
],
[
147,
24,... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil (Compound) resembles Uracil mustard (Compound) and Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fluorouracil may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Fluorouracil may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Fluorouracil may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate |
DB00159 | DB00208 | 940 | 1,018 | [
"DDInter903",
"DDInter1804"
] | Icosapent | Ticlopidine | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Moderate | 1 | [
[
[
940,
24,
1018
]
],
[
[
940,
24,
1347
],
[
1347,
64,
1018
]
],
[
[
940,
18,
10375
],
[
10375,
57,
1018
]
],
[
[
940,
21,
28957
],
[
289... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Icosapent (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Ticlopidine (Compound)
Icosapent (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Ticlopidine (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Ticlopidine
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Ticlopidine (Compound)
Icosapent (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Clopidogrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine
Icosapent (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Ticlopidine |
DB00526 | DB00631 | 1,555 | 372 | [
"DDInter1355",
"DDInter405"
] | Oxaliplatin | Clofarabine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Moderate | 1 | [
[
[
1555,
24,
372
]
],
[
[
1555,
64,
1064
],
[
1064,
25,
372
]
],
[
[
1555,
24,
1488
],
[
1488,
40,
372
]
],
[
[
1555,
6,
17404
],
[
17404... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladrib... | Oxaliplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles Clofarabine (Compound)
Oxaliplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine
Oxaliplatin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide and Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine |
DB00285 | DB00792 | 1,100 | 832 | [
"DDInter1927",
"DDInter1878"
] | Venlafaxine | Tripelennamine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1100,
24,
832
]
],
[
[
1100,
24,
100
],
[
100,
63,
832
]
],
[
[
1100,
25,
1264
],
[
1264,
63,
832
]
],
[
[
1100,
24,
649
],
[
649,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Venlafaxine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Tripelennamine (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Venlafaxine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tripelennamine (Compound)
Venlafaxine (Compound) resembles Tramadol (Compound) and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Venlafaxine (Compound) resembles Desvenlafaxine (Compound) and Des
Venlafaxine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine |
DB01132 | DB04865 | 1,130 | 4 | [
"DDInter1472",
"DDInter1335"
] | Pioglitazone | Omacetaxine mepesuccinate | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglit | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML. | Moderate | 1 | [
[
[
1130,
24,
4
]
],
[
[
1130,
18,
2475
],
[
2475,
46,
4
]
],
[
[
1130,
7,
4698
],
[
4698,
57,
4
]
],
[
[
1130,
63,
485
],
[
485,
24... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Pioglitazone",
"{u} (Compound) downregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is up... | Pioglitazone (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Pioglitazone (Compound) upregulates GPC1 (Gene) and GPC1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Pioglitazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Pioglitazone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate |
DB01050 | DB08901 | 848 | 1,468 | [
"DDInter900",
"DDInter1492"
] | Ibuprofen | Ponatinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
848,
25,
1468
]
],
[
[
848,
6,
3486
],
[
3486,
45,
1468
]
],
[
[
848,
6,
4789
],
[
4789,
57,
1468
]
],
[
[
848,
21,
29024
],
[
29024,
... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"... | Ibuprofen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ponatinib (Compound)
Ibuprofen (Compound) binds PPARG (Gene) and PPARG (Gene) is downregulated by Ponatinib (Compound)
Ibuprofen (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Ibuprofen may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB00270 | DB04868 | 1,428 | 478 | [
"DDInter993",
"DDInter1293"
] | Isradipine | Nilotinib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1428,
24,
478
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1428,
7,
10670
],
[
10670,
46,
478
]
],
[
[
1428,
18,
8800
],
[
8800,... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Isradipine (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Nilotinib (Compound)
Isradipine (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Nilotinib (Compound)
Isradipine (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00539 | DB00934 | 11 | 413 | [
"DDInter1837",
"DDInter1124"
] | Toremifene | Maprotiline | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Major | 2 | [
[
[
11,
25,
413
]
],
[
[
11,
64,
1302
],
[
1302,
40,
413
]
],
[
[
11,
64,
847
],
[
847,
1,
413
]
],
[
[
11,
6,
4973
],
[
4973,
45,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Maprotiline"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
... | Toremifene may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Toremifene may lead to a major life threatening interaction when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline (Compound)
Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Maprotiline (Compound)
Toremifene (Compound) upregulates EBP (Gene) and EBP (Gene) is upregulated by Maprotiline (Compound)
Toremifene (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Maprotiline (Compound)
Toremifene (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Maprotiline (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Maprotiline
Toremifene may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline
Toremifene may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Maprotiline |
DB00697 | DB06803 | 876 | 769 | [
"DDInter1821",
"DDInter1288"
] | Tizanidine | Niclosamide | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Niclosamide is an antihelminthic used for the treatment of tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996. | Major | 2 | [
[
[
876,
25,
769
]
],
[
[
876,
6,
7950
],
[
7950,
45,
769
]
],
[
[
876,
18,
8386
],
[
8386,
46,
769
]
],
[
[
876,
18,
4930
],
[
4930,
... | [
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niclosamide"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Niclos... | Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Niclosamide (Compound)
Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Niclosamide (Compound)
Tizanidine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Niclosamide (Compound)
Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Niclosamide
Tizanidine (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Triclosan (Compound) and Triclosan (Compound) resembles Niclosamide (Compound)
Tizanidine (Compound) downregulates DLD (Gene) and DLD (Gene) is regulated by MARS (Gene) and MARS (Gene) is upregulated by Niclosamide (Compound)
Tizanidine (Compound) resembles Clonidine (Compound) and Clonidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Niclosamide (Compound)
Tizanidine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Triclosan (Compound) and Triclosan (Compound) resembles Niclosamide (Compound)
Tizanidine (Compound) downregulates DLD (Gene) and DLD (Gene) regulates VAT1 (Gene) and VAT1 (Gene) is upregulated by Niclosamide (Compound) |
DB00284 | DB01278 | 1,647 | 1,021 | [
"DDInter11",
"DDInter1506"
] | Acarbose | Pramlintide | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1647,
24,
1021
]
],
[
[
1647,
23,
1103
],
[
1103,
23,
1021
]
],
[
[
1647,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
1647,
24,
1680
],
[
16... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Acarbose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"... | Acarbose may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Pramlintide
Acarbose may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide |
DB00883 | DB01143 | 426 | 923 | [
"DDInter989",
"DDInter65"
] | Isosorbide dinitrate | Amifostine | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
426,
24,
923
]
],
[
[
426,
21,
28642
],
[
28642,
60,
923
]
],
[
[
426,
40,
1107
],
[
1107,
24,
923
]
],
[
[
426,
24,
714
],
[
714,
... | [
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Eff... | Isosorbide dinitrate (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound) and Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate (Compound) resembles Isosorbide mononitrate (Compound) and Isosorbide mononitrate (Compound) causes Supraventricular tachycardia (Side Effect) and Supraventricular tachycardia (Side Effect) is caused by Amifostine (Compound)
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound) |
DB00559 | DB11901 | 152 | 913 | [
"DDInter223",
"DDInter107"
] | Bosentan | Apalutamide | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
152,
24,
913
]
],
[
[
152,
24,
112
],
[
112,
23,
913
]
],
[
[
152,
62,
608
],
[
608,
23,
913
]
],
[
[
152,
63,
600
],
[
600,
24,... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Bosentan may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib and Abemaciclib may lead to a major life threatening interaction when taken with Apalutamide
Bosentan may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Apalutamide
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Apalutamide |
DB00342 | DB06595 | 1,181 | 1,491 | [
"DDInter1770",
"DDInter1214"
] | Terfenadine | Midostaurin | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
1181,
24,
1491
]
],
[
[
1181,
23,
112
],
[
112,
23,
1491
]
],
[
[
1181,
24,
888
],
[
888,
24,
1491
]
],
[
[
1181,
24,
1017
],
[
1017,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Vasopressin and Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Terfenadine may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may lead to a major life threatening interaction when taken with Midostaurin
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Midostaurin |
DB01067 | DB01193 | 959 | 819 | [
"DDInter826",
"DDInter12"
] | Glipizide | Acebutolol | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
959,
24,
819
]
],
[
[
959,
63,
887
],
[
887,
1,
819
]
],
[
[
959,
21,
28762
],
[
28762,
60,
819
]
],
[
[
959,
63,
417
],
[
417,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Glipizide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Acebutolol (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Acebutolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Acebutolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol
Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol |
DB00816 | DB11730 | 1,674 | 351 | [
"DDInter1346",
"DDInter1588"
] | Orciprenaline | Ribociclib | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
1674,
25,
351
]
],
[
[
1674,
24,
222
],
[
222,
23,
351
]
],
[
[
1674,
63,
867
],
[
867,
24,
351
]
],
[
[
1674,
23,
1486
],
[
1486,
... | [
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sib... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Ribociclib
Orciprenaline may lead to a major life threatening interaction when taken with Amisulpride and Amisulpride may lead to a major life threatening interaction when taken with Ribociclib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib |
DB00470 | DB01238 | 530 | 673 | [
"DDInter601",
"DDInter118"
] | Dronabinol | Aripiprazole | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Moderate | 1 | [
[
[
530,
24,
673
]
],
[
[
530,
24,
851
],
[
851,
1,
673
]
],
[
[
530,
24,
827
],
[
827,
40,
673
]
],
[
[
530,
6,
4973
],
[
4973,
45,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Dronabinol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Aripiprazole (Compound)
Dronabinol (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Aripiprazole (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Aripiprazole |
DB00305 | DB01097 | 377 | 1,377 | [
"DDInter1232",
"DDInter1033"
] | Mitomycin | Leflunomide | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
377,
25,
1377
]
],
[
[
377,
18,
4930
],
[
4930,
57,
1377
]
],
[
[
377,
21,
28701
],
[
28701,
60,
1377
]
],
[
[
377,
63,
1461
],
[
1461... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Mitomycin",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Mitomycin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Leflunomide (Compound)
Mitomycin (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may lead to a major life threatening interaction when taken with Leflunomide
Mitomycin may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Leflunomide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Leflunomide |
DB00569 | DB06779 | 553 | 365 | [
"DDInter775",
"DDInter470"
] | Fondaparinux | Dalteparin | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Major | 2 | [
[
[
553,
25,
365
]
],
[
[
553,
23,
539
],
[
539,
62,
365
]
],
[
[
553,
63,
305
],
[
305,
24,
365
]
],
[
[
553,
24,
1496
],
[
1496,
6... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Fondaparinux",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Fondaparinux may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin
Fondaparinux may lead to a major life threatening interaction when taken with Ketoprofen and Ketoprofen may lead to a major life threatening interaction when taken with Dalteparin
Fondaparinux may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Dalteparin
Fondaparinux (Compound) resembles Ardeparin (Compound) and Fondaparinux may lead to a major life threatening interaction when taken with Ardeparin and Ardeparin may lead to a major life threatening interaction when taken with Dalteparin
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Dalteparin |
DB00450 | DB06788 | 78 | 1,616 | [
"DDInter603",
"DDInter864"
] | Droperidol | Histrelin | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Major | 2 | [
[
[
78,
25,
1616
]
],
[
[
78,
23,
112
],
[
112,
23,
1616
]
],
[
[
78,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
78,
24,
603
],
[
603,
63... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Droperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Histrelin
Droperidol may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Histrelin |
DB00459 | DB09389 | 640 | 517 | [
"DDInter21",
"DDInter1315"
] | Acitretin | Norgestrel | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Major | 2 | [
[
[
640,
25,
517
]
],
[
[
640,
25,
1517
],
[
1517,
24,
517
]
],
[
[
640,
24,
1411
],
[
1411,
24,
517
]
],
[
[
640,
63,
305
],
[
305,
... | [
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u}... | Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Acitretin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Norgestrel
Acitretin may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Acitretin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel |
DB00047 | DB00574 | 176 | 121 | [
"DDInter932",
"DDInter717"
] | Insulin glargine | Fenfluramine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis. Insulin is an important treatment in the management of Type 1 Diabetes (T1D), which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome and Lennox-Gastaut syndrome through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC. | Moderate | 1 | [
[
[
176,
24,
121
]
],
[
[
176,
24,
127
],
[
127,
24,
121
]
],
[
[
176,
24,
659
],
[
659,
63,
121
]
],
[
[
176,
24,
341
],
[
341,
64,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine and Phendimetrazine may lead to a major life threatening interaction when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may lead to a major life threatening interaction when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Fenfluramine |
DB00026 | DB11952 | 1,184 | 800 | [
"DDInter94",
"DDInter612"
] | Anakinra | Duvelisib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
1184,
24,
800
]
],
[
[
1184,
24,
310
],
[
310,
24,
800
]
],
[
[
1184,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1184,
25,
1292
],
[
1292,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Anakinra may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Duvelisib
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Duvelisib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Duvelisib
Anakinra may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Duvelisib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib |
DB00414 | DB00501 | 590 | 752 | [
"DDInter16",
"DDInter380"
] | Acetohexamide | Cimetidine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Moderate | 1 | [
[
[
590,
24,
752
]
],
[
[
590,
24,
935
],
[
935,
62,
752
]
],
[
[
590,
63,
831
],
[
831,
23,
752
]
],
[
[
590,
24,
886
],
[
886,
23,... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Acetohexamide may lead to a major life threatening interaction when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and Brexpiprazole may lead to a major life threatening interaction when taken with Cimetidine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Cimetidine |
DB00270 | DB09133 | 1,428 | 1,527 | [
"DDInter993",
"DDInter965"
] | Isradipine | Iothalamic acid | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
1428,
24,
1527
]
],
[
[
1428,
24,
278
],
[
278,
63,
1527
]
],
[
[
1428,
1,
84
],
[
84,
24,
1527
]
],
[
[
1428,
24,
512
],
[
512,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid and Iopanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Iothalamic acid
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid |
DB00574 | DB01132 | 121 | 1,130 | [
"DDInter717",
"DDInter1472"
] | Fenfluramine | Pioglitazone | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARγ). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis. Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus. | Moderate | 1 | [
[
[
121,
24,
1130
]
],
[
[
121,
25,
851
],
[
851,
63,
1130
]
],
[
[
121,
24,
688
],
[
688,
24,
1130
]
],
[
[
121,
24,
320
],
[
320,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefa... | Fenfluramine may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine and Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Pioglitazone
Fenfluramine may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pioglitazone (Compound) |
DB00934 | DB00938 | 413 | 455 | [
"DDInter1124",
"DDInter1635"
] | Maprotiline | Salmeterol | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Moderate | 1 | [
[
[
413,
24,
455
]
],
[
[
413,
24,
688
],
[
688,
63,
455
]
],
[
[
413,
7,
9650
],
[
9650,
46,
455
]
],
[
[
413,
18,
2183
],
[
2183,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Maprotiline (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Salmeterol (Compound)
Maprotiline (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Salmeterol (Compound)
Maprotiline (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Salmeterol (Compound)
Maprotiline may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Maprotiline may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Maprotiline (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol |
DB00902 | DB11827 | 104 | 433 | [
"DDInter1168",
"DDInter669"
] | Methdilazine | Ertugliflozin | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
104,
24,
433
]
],
[
[
104,
63,
1020
],
[
1020,
24,
433
]
],
[
[
104,
24,
959
],
[
959,
24,
433
]
],
[
[
104,
40,
820
],
[
820,
2... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine (Compound) resembles Perphenazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine (Compound) resembles Quetiapine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine (Compound) resembles Thioridazine (Compound) and Methdilazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin |
DB00252 | DB09481 | 362 | 460 | [
"DDInter1460",
"DDInter1113"
] | Phenytoin | Magnesium carbonate | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications such as bipolar disorder, retina protection, and wound healing.[A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal treatment, or adverse effects.[A189219,A35884] Both parenteral and oral formulations of phenytoin are available on the market. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
362,
24,
460
]
],
[
[
362,
24,
401
],
[
401,
23,
460
]
],
[
[
362,
25,
752
],
[
752,
23,
460
]
],
[
[
362,
63,
1018
],
[
1018,
2... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Phenytoin may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Phenytoin may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Phenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Phenytoin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Phenytoin (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate |
DB00557 | DB11718 | 252 | 927 | [
"DDInter895",
"DDInter640"
] | Hydroxyzine | Encorafenib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Moderate | 1 | [
[
[
252,
24,
927
]
],
[
[
252,
23,
112
],
[
112,
23,
927
]
],
[
[
252,
24,
720
],
[
720,
24,
927
]
],
[
[
252,
63,
1010
],
[
1010,
2... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Hydroxyzine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Hydroxyzine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Encorafenib
Hydroxyzine (Compound) resembles Nefazodone (Compound) and Nefazodone may lead to a major life threatening interaction when taken with Encorafenib |
DB06605 | DB12825 | 1,409 | 1,375 | [
"DDInter108",
"DDInter1032"
] | Apixaban | Lefamulin | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity. | Moderate | 1 | [
[
[
1409,
24,
1375
]
],
[
[
1409,
24,
159
],
[
159,
63,
1375
]
],
[
[
1409,
63,
1101
],
[
1101,
24,
1375
]
],
[
[
1409,
24,
98
],
[
98,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apixaban may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apixaban may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
Apixaban may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Lefamulin
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Lefamulin
Apixaban may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Lefamulin |
DB00434 | DB00502 | 13 | 1,300 | [
"DDInter459",
"DDInter853"
] | Cyproheptadine | Haloperidol | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is theorized to be caused by a hyperdopaminergic state within the limbic system of the brain. Use of the first-generation antipsychotics (including haloperidol) is considered highly effective for the management of the "positive" symptoms of schizophrenia including hallucinations, hearing voices, aggression/hostility, disorganized speech, and psychomotor agitation. However, this class of drugs is also limited by the development of movement disorders induced by dopamine-blockade such as drug-induced parkinsonism, akathisia, dystonia, tardive dyskinesia, as well as other side effects including sedation, weight gain, and prolactin changes. While there are limited high-quality studies comparing haloperidol to lower-potency first-generation antipsychotics such as , , , and , haloperidol typically demonstrates the least amount of side effects within this class, but demonstrates a stronger disposition for causing extrapyramidal symptoms (EPS).[A180613, A180616, A180625] These other low‐potency antipsychotics are limited by their lower affinity for dopamine receptors, which requires a higher dose to effectively treat symptoms of schizophrenia. In addition, they block many receptors other than the primary target (dopamine receptors), such as cholinergic or histaminergic receptors, resulting in a higher incidence of side effects such as sedation, weight gain, and hypotension. Interestingly, in vivo pharmacogenetic studies have demonstrated that the metabolism of haloperidol may be modulated by genetically determined polymorphic _CYP2D6_ activity. However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo. Inter-ethnic and pharmacogenetic differences in haloperidol metabolism may possibly explain these observations. First-generation antipsychotic drugs have largely been replaced with second- and third-generation (atypical) antipsychotics such as , , , , , and . However, haloperidol use remains widespread and is considered the benchmark for comparison in trials of the newer generation antipsychotics. The efficacy of haloperidol was first established in controlled trials in the 1960s. | Moderate | 1 | [
[
[
13,
24,
1300
]
],
[
[
13,
24,
78
],
[
78,
1,
1300
]
],
[
[
13,
24,
543
],
[
543,
63,
1300
]
],
[
[
13,
63,
1242
],
[
1242,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
],... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Haloperidol (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol
Cyproheptadine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Haloperidol (Compound)
Cyproheptadine (Compound) palliates schizophrenia (Disease) and schizophrenia (Disease) is palliated by Haloperidol (Compound)
Cyproheptadine (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Haloperidol (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Haloperidol
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Haloperidol |
DB00902 | DB01142 | 104 | 1,264 | [
"DDInter1168",
"DDInter593"
] | Methdilazine | Doxepin | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
104,
24,
1264
]
],
[
[
104,
40,
508
],
[
508,
24,
1264
]
],
[
[
104,
24,
401
],
[
401,
24,
1264
]
],
[
[
104,
63,
1594
],
[
1594,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate... | Methdilazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Methdilazine (Compound) resembles Imipramine (Compound) and Imipramine (Compound) resembles Doxepin (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may lead to a major life threatening interaction when taken with Doxepin
Methdilazine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Doxepin (Compound)
Methdilazine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Doxepin (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa may cause a minor interaction that can limit clinical effects when taken with Doxepin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methyldopa may cause a minor interaction that can limit clinical effects when taken with Doxepin |
DB00262 | DB15091 | 552 | 676 | [
"DDInter302",
"DDInter1901"
] | Carmustine | Upadacitinib | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration. | Major | 2 | [
[
[
552,
25,
676
]
],
[
[
552,
63,
1461
],
[
1461,
23,
676
]
],
[
[
552,
24,
1430
],
[
1430,
24,
676
]
],
[
[
552,
25,
752
],
[
752,
... | [
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Carmustine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may lead to a major life threatening interaction when taken with Upadacitinib
Carmustine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib
Carmustine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Upadacitinib
Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Upadacitinib
Carmustine (Compound) resembles Lomustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may lead to a major life threatening interaction when taken with Upadacitinib |
DB00041 | DB00524 | 1,648 | 811 | [
"DDInter38",
"DDInter1199"
] | Aldesleukin | Metolazone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
1648,
24,
811
]
],
[
[
1648,
24,
1605
],
[
1605,
40,
811
]
],
[
[
1648,
24,
1014
],
[
1014,
1,
811
]
],
[
[
1648,
24,
1042
],
[
1042,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Metolazone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Chlorthalidone (Compound) and Chlorthalidone (Compound) resembles Metolazone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound) |
DB00258 | DB09100 | 666 | 320 | [
"DDInter270",
"DDInter1799"
] | Calcium acetate | Thyroid, porcine | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA. | Moderate | 1 | [
[
[
666,
24,
320
]
],
[
[
666,
24,
1231
],
[
1231,
24,
320
]
],
[
[
666,
21,
28845
],
[
28845,
60,
417
],
[
417,
23,
320
]
],
[
[
666,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Calcium acetate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Sucralfate (Compound) and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous and Calcium glubionate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Calcium acetate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine |
DB00041 | DB00741 | 1,648 | 167 | [
"DDInter38",
"DDInter885"
] | Aldesleukin | Hydrocortisone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Moderate | 1 | [
[
[
1648,
24,
167
]
],
[
[
1648,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1648,
24,
443
],
[
443,
24,
167
]
],
[
[
1648,
24,
1364
],
[
1364,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Aldesleukin may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may lead to a major life threatening interaction when taken with Hydrocortisone
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Hydrocortisone
Aldesleukin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Hydrocortisone
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol may lead to a major life threatening interaction when taken with Hydrocortisone |
DB01267 | DB12141 | 519 | 971 | [
"DDInter1381",
"DDInter817"
] | Paliperidone | Gilteritinib | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749] | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
519,
24,
971
]
],
[
[
519,
62,
112
],
[
112,
23,
971
]
],
[
[
519,
63,
485
],
[
485,
24,
971
]
],
[
[
519,
24,
823
],
[
823,
63,... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Paliperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Paliperidone (Compound) resembles Risperidone (Compound) and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Paliperidone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Paliperidone may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Gilteritinib
Paliperidone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Gilteritinib
Paliperidone may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Gilteritinib |
DB06043 | DB11003 | 1,644 | 748 | [
"DDInter1328",
"DDInter100"
] | Olaratumab | Anthrax vaccine | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
1644,
24,
748
]
],
[
[
1644,
25,
676
],
[
676,
63,
748
]
],
[
[
1644,
63,
1683
],
[
1683,
24,
748
]
],
[
[
1644,
64,
1057
],
[
1057,
... | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upa... | Olaratumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Olaratumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00694 | DB06788 | 51 | 1,616 | [
"DDInter485",
"DDInter864"
] | Daunorubicin | Histrelin | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007). | Moderate | 1 | [
[
[
51,
24,
1616
]
],
[
[
51,
23,
112
],
[
112,
23,
1616
]
],
[
[
51,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
51,
35,
77
],
[
77,
24,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Daunorubicin may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin |
DB00526 | DB11986 | 1,555 | 484 | [
"DDInter1355",
"DDInter648"
] | Oxaliplatin | Entrectinib | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Moderate | 1 | [
[
[
1555,
24,
484
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
484
]
],
[
[
1555,
24,
112
],
[
112,
23,
484
]
],
[
[
1555,
24,
1539
],
[
1539,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Oxaliplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Oxaliplatin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Oxaliplatin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Oxaliplatin may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Entrectinib |
DB00757 | DB01224 | 1,166 | 623 | [
"DDInter581",
"DDInter1553"
] | Dolasetron | Quetiapine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors. | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine]. | Major | 2 | [
[
[
1166,
25,
623
]
],
[
[
1166,
64,
827
],
[
827,
1,
623
]
],
[
[
1166,
25,
851
],
[
851,
1,
623
]
],
[
[
1166,
63,
867
],
[
867,
1... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quetiapine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} (Co... | Dolasetron may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Quetiapine (Compound)
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine (Compound) resembles Quetiapine (Compound)
Dolasetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Quetiapine (Compound)
Dolasetron (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Quetiapine (Compound)
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quetiapine
Dolasetron may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quetiapine
Dolasetron may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine
Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine |
DB00397 | DB06335 | 1,466 | 761 | [
"DDInter1458",
"DDInter1646"
] | Phenylpropanolamine | Saxagliptin | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1466,
24,
761
]
],
[
[
1466,
21,
28722
],
[
28722,
60,
761
]
],
[
[
1466,
24,
104
],
[
104,
24,
761
]
],
[
[
1466,
24,
1296
],
[
1296,... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Ef... | Phenylpropanolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine (Compound) resembles Pseudoephedrine (Compound) and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine (Compound) resembles Metamfetamine (Compound) and Phenylpropanolamine may lead to a major life threatening interaction when taken with Metamfetamine and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Phenylpropanolamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Vildagliptin (Compound) and Vildagliptin (Compound) resembles Saxagliptin (Compound) |
DB00254 | DB00564 | 964 | 1,236 | [
"DDInter598",
"DDInter293"
] | Doxycycline | Carbamazepine | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Moderate | 1 | [
[
[
964,
24,
1236
]
],
[
[
964,
63,
362
],
[
362,
1,
1236
]
],
[
[
964,
6,
8374
],
[
8374,
45,
1236
]
],
[
[
964,
24,
1031
],
[
1031,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Doxycycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carbamazepine (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal and Activated charcoal may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Doxycycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Carbamazepine
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound) and Modafinil (Compound) resembles Carbamazepine (Compound) |
DB08881 | DB11642 | 868 | 938 | [
"DDInter1925",
"DDInter1480"
] | Vemurafenib | Pitolisant | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Major | 2 | [
[
[
868,
25,
938
]
],
[
[
868,
62,
112
],
[
112,
23,
938
]
],
[
[
868,
24,
760
],
[
760,
24,
938
]
],
[
[
868,
64,
600
],
[
600,
24,... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may lead to a major life threatening interaction when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Vemurafenib may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Pitolisant
Vemurafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Pitolisant |
DB00289 | DB00581 | 847 | 355 | [
"DDInter132",
"DDInter1018"
] | Atomoxetine | Lactulose | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the fact that lactulose therapy cannot be ethically withheld from patients diagnosed with PSE in a placebo study, the substance may just be one of many options available for treating constipation and its efficacy in managing PSE may never be formally confirmed or refuted via clinical investigation. | Moderate | 1 | [
[
[
847,
24,
355
]
],
[
[
847,
21,
28750
],
[
28750,
60,
355
]
],
[
[
847,
24,
286
],
[
286,
62,
355
]
],
[
[
847,
24,
79
],
[
79,
2... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Atomoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u... | Atomoxetine (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Lactulose (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Lactulose
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Atomoxetine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose |
DB06605 | DB09034 | 1,409 | 1,313 | [
"DDInter108",
"DDInter1733"
] | Apixaban | Suvorexant | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
1409,
24,
1313
]
],
[
[
1409,
64,
1213
],
[
1213,
24,
1313
]
],
[
[
1409,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
1409,
63,
353
],
[
353... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Apixaban may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Apixaban may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Suvorexant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Suvorexant
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Suvorexant |
DB09121 | DB12834 | 1,328 | 148 | [
"DDInter140",
"DDInter1649"
] | Aurothioglucose | Secnidazole | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis. The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective. | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen. Secnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades.[A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis. | Moderate | 1 | [
[
[
1328,
24,
148
]
],
[
[
1328,
63,
1593
],
[
1593,
24,
148
]
],
[
[
1328,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1328,
64,
1487
],
[
1487,... | [
[
[
"Aurothioglucose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Aurothioglucose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
... | Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Aurothioglucose may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole |
DB00682 | DB01598 | 126 | 483 | [
"DDInter1951",
"DDInter911"
] | Warfarin | Imipenem | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins. Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co. | Moderate | 1 | [
[
[
126,
24,
483
]
],
[
[
126,
24,
593
],
[
593,
25,
483
]
],
[
[
126,
62,
1533
],
[
1533,
7,
13852
],
[
13852,
46,
483
]
],
[
[
126,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imipenem"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bu... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Imipenem
Warfarin may cause a minor interaction that can limit clinical effects when taken with Entacapone and Entacapone (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Imipenem (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Imipenem (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Imipenem (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Imipenem
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Imipenem (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Imipenem
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) downregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Imipenem (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Imipenem |
DB08907 | DB13007 | 1,344 | 1,060 | [
"DDInter280",
"DDInter642"
] | Canagliflozin | Enfortumab vedotin | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus, [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes. Cardiovascular disease is the most common cause of death in these patients. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1344,
24,
1060
]
],
[
[
1344,
63,
590
],
[
590,
24,
1060
]
],
[
[
1344,
40,
549
],
[
549,
24,
1060
]
],
[
[
1344,
24,
1296
],
[
1296,
... | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide... | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin |
DB00055 | DB01166 | 834 | 477 | [
"DDInter605",
"DDInter379"
] | Drotrecogin alfa | Cilostazol | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Major | 2 | [
[
[
834,
25,
477
]
],
[
[
834,
25,
126
],
[
126,
23,
477
]
],
[
[
834,
23,
539
],
[
539,
62,
477
]
],
[
[
834,
24,
109
],
[
109,
24,... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Drotrecogin alfa may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Drotrecogin alfa may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Drotrecogin alfa may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Drotrecogin alfa may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Cilostazol
Drotrecogin alfa may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Cilostazol |
DB00490 | DB09098 | 946 | 98 | [
"DDInter254",
"DDInter1700"
] | Buspirone | Somatrem | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
946,
24,
98
]
],
[
[
946,
24,
159
],
[
159,
63,
98
]
],
[
[
946,
24,
609
],
[
609,
24,
98
]
],
[
[
946,
25,
222
],
[
222,
24,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Buspirone may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Buspirone may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00683 | DB08904 | 1,382 | 375 | [
"DDInter1212",
"DDInter342"
] | Midazolam | Certolizumab pegol | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019 | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Moderate | 1 | [
[
[
1382,
24,
375
]
],
[
[
1382,
24,
1593
],
[
1593,
24,
375
]
],
[
[
1382,
63,
608
],
[
608,
24,
375
]
],
[
[
1382,
1,
902
],
[
902,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Midazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Midazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Certolizumab pegol
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Midazolam may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone may lead to a major life threatening interaction when taken with Certolizumab pegol
Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may lead to a major life threatening interaction when taken with Certolizumab pegol
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB08816 | DB09075 | 578 | 498 | [
"DDInter1802",
"DDInter621"
] | Ticagrelor | Edoxaban | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy. | Major | 2 | [
[
[
578,
25,
498
]
],
[
[
578,
23,
944
],
[
944,
62,
498
]
],
[
[
578,
24,
1004
],
[
1004,
63,
498
]
],
[
[
578,
24,
41
],
[
41,
24,... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Ticagrelor may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban |
DB01101 | DB10315 | 60 | 1,137 | [
"DDInter285",
"DDInter1127"
] | Capecitabine | Measles virus vaccine live attenuated | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
60,
25,
1137
]
],
[
[
60,
64,
581
],
[
581,
25,
1137
]
],
[
[
60,
24,
384
],
[
384,
25,
1137
]
],
[
[
60,
63,
1184
],
[
1184,
25... | [
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Capecitabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
... | Capecitabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Ixabepilone and Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Capecitabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated |
DB01044 | DB08881 | 246 | 868 | [
"DDInter809",
"DDInter1925"
] | Gatifloxacin | Vemurafenib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Major | 2 | [
[
[
246,
25,
868
]
],
[
[
246,
6,
1829
],
[
1829,
45,
868
]
],
[
[
246,
7,
2067
],
[
2067,
46,
868
]
],
[
[
246,
18,
8386
],
[
8386,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafe... | Gatifloxacin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Gatifloxacin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Vemurafenib (Compound)
Gatifloxacin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Gatifloxacin (Compound) downregulates PGAM1 (Gene) and PGAM1 (Gene) is downregulated by Vemurafenib (Compound)
Gatifloxacin (Compound) upregulates CCNB1 (Gene) and CCNB1 (Gene) is downregulated by Vemurafenib (Compound)
Gatifloxacin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB08895 | DB14881 | 976 | 180 | [
"DDInter1825",
"DDInter1329"
] | Tofacitinib | Oliceridine | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists.[A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and respiratory depression.[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin.[A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse effects such as constipation and respiratory depression.[A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. | Moderate | 1 | [
[
[
976,
24,
180
]
],
[
[
976,
64,
1184
],
[
1184,
24,
180
]
],
[
[
976,
25,
1476
],
[
1476,
24,
180
]
],
[
[
976,
24,
1297
],
[
1297,
... | [
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra"... | Tofacitinib may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Tofacitinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Oliceridine
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Oliceridine
Tofacitinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Oliceridine
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Oliceridine
Tofacitinib may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine |
DB00312 | DB11979 | 1,023 | 1,320 | [
"DDInter1423",
"DDInter625"
] | Pentobarbital | Elagolix | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
1023,
24,
1320
]
],
[
[
1023,
62,
168
],
[
168,
23,
1320
]
],
[
[
1023,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1023,
24,
877
],
[
877,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Pentobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Elagolix
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Nafcillin and Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix |
DB00860 | DB09263 | 891 | 1,436 | [
"DDInter1513",
"DDInter1399"
] | Prednisolone | Patiromer | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. | Moderate | 1 | [
[
[
891,
24,
1436
]
],
[
[
891,
40,
1220
],
[
1220,
24,
1436
]
],
[
[
891,
23,
1114
],
[
1114,
63,
1436
]
],
[
[
891,
63,
1645
],
[
1645,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause ... | Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Patiromer
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may lead to a major life threatening interaction when taken with Patiromer
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Prednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer |
DB00877 | DB15093 | 629 | 1,654 | [
"DDInter1678",
"DDInter1698"
] | Sirolimus | Somapacitan | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
629,
24,
1654
]
],
[
[
629,
63,
608
],
[
608,
23,
1654
]
],
[
[
629,
63,
10
],
[
10,
24,
1654
]
],
[
[
629,
24,
433
],
[
433,
24... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sirolimus may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00884 | DB09481 | 1,008 | 460 | [
"DDInter1604",
"DDInter1113"
] | Risedronic acid | Magnesium carbonate | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1008,
24,
460
]
],
[
[
1008,
24,
853
],
[
853,
24,
460
]
],
[
[
1008,
24,
428
],
[
428,
63,
460
]
],
[
[
1008,
40,
1485
],
[
1485,
... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesiu... | Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride and Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Risedronic acid (Compound) resembles Alendronic acid (Compound) and Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate |
DB04845 | DB11003 | 309 | 748 | [
"DDInter1001",
"DDInter100"
] | Ixabepilone | Anthrax vaccine | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
309,
24,
748
]
],
[
[
309,
63,
168
],
[
168,
24,
748
]
],
[
[
309,
25,
676
],
[
676,
63,
748
]
],
[
[
309,
24,
1683
],
[
1683,
2... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00446 | DB01177 | 597 | 77 | [
"DDInter351",
"DDInter904"
] | Chloramphenicol | Idarubicin | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
597,
24,
77
]
],
[
[
597,
6,
6017
],
[
6017,
45,
77
]
],
[
[
597,
7,
2903
],
[
2903,
46,
77
]
],
[
[
597,
18,
8527
],
[
8527,
57... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (C... | Chloramphenicol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Chloramphenicol (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Idarubicin (Compound)
Chloramphenicol (Compound) downregulates UBE2S (Gene) and UBE2S (Gene) is downregulated by Idarubicin (Compound)
Chloramphenicol (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Idarubicin (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline and Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Chloramphenicol may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin |
DB00188 | DB00330 | 168 | 238 | [
"DDInter222",
"DDInter689"
] | Bortezomib | Ethambutol | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. Ethambutol was granted FDA approval on 6 November 1967. | Moderate | 1 | [
[
[
168,
24,
238
]
],
[
[
168,
7,
10670
],
[
10670,
46,
238
]
],
[
[
168,
21,
29062
],
[
29062,
60,
238
]
],
[
[
168,
64,
1057
],
[
1057,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethambutol"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL21"
],
[
"KLHL21",
"{u} (Gene) is upregulated by {v} ... | Bortezomib (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Ethambutol (Compound)
Bortezomib (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Ethambutol (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Bortezomib may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Bortezomib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ethambutol
Bortezomib (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol |
DB00622 | DB06273 | 1,081 | 980 | [
"DDInter1287",
"DDInter1824"
] | Nicardipine | Tocilizumab | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem] | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023. | Moderate | 1 | [
[
[
1081,
24,
980
]
],
[
[
1081,
40,
1428
],
[
1428,
24,
980
]
],
[
[
1081,
24,
629
],
[
629,
24,
980
]
],
[
[
1081,
63,
58
],
[
58,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Isradipine"
],
[
"Isradipine",
"{u} may cause a mode... | Nicardipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Tocilizumab
Nicardipine (Compound) resembles Isradipine (Compound) and Isradipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Nicardipine (Compound) resembles Nifedipine (Compound) and Nifedipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab |
DB01246 | DB14740 | 820 | 771 | [
"DDInter45",
"DDInter881"
] | Alimemazine | Hyaluronidase | A phenothiazine derivative that is used as an antipruritic. | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. Hyaluronidase was first used in prescription products in the United States on 5 May 2004. | Minor | 0 | [
[
[
820,
23,
771
]
],
[
[
820,
24,
849
],
[
849,
23,
771
]
],
[
[
820,
63,
1242
],
[
1242,
23,
771
]
],
[
[
820,
74,
1376
],
[
1376,
... | [
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine and Phenyltoloxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase |
DB01234 | DB09082 | 1,220 | 659 | [
"DDInter513",
"DDInter1934"
] | Dexamethasone | Vilanterol | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Minor | 0 | [
[
[
1220,
23,
659
]
],
[
[
1220,
1,
891
],
[
891,
23,
659
]
],
[
[
1220,
40,
1573
],
[
1573,
23,
659
]
],
[
[
1220,
24,
1296
],
[
1296,
... | [
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a... | Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Dexamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol |
DB00777 | DB06704 | 146 | 247 | [
"DDInter1537",
"DDInter951"
] | Propiomazine | Iobenguane (I-123) | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
146,
24,
247
]
],
[
[
146,
40,
820
],
[
820,
24,
247
]
],
[
[
146,
1,
104
],
[
104,
24,
247
]
],
[
[
146,
25,
497
],
[
497,
25,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a m... | Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Propiomazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Propiomazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Propiomazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Iobenguane
Propiomazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Trimipramine may lead to a major life threatening interaction when taken with Iobenguane
Propiomazine (Compound) resembles Alimemazine (Compound) and Alimemazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Propiomazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine (Compound) upregulates HLA-DMA (Gene) and HLA-DMA (Gene) is upregulated by Iobenguane (Compound)
Propiomazine (Compound) resembles Thioridazine (Compound) and Thioridazine (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Iobenguane (Compound)
Propiomazine (Compound) resembles Promazine (Compound) and Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Propiomazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane |
DB00372 | DB06691 | 999 | 849 | [
"DDInter1793",
"DDInter1155"
] | Thiethylperazine | Mepyramine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
999,
24,
849
]
],
[
[
999,
63,
1594
],
[
1594,
24,
849
]
],
[
[
999,
24,
272
],
[
272,
24,
849
]
],
[
[
999,
24,
1116
],
[
1116,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may lead to a major life threatening interaction when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Mepyramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB11793 | DB11817 | 738 | 1,259 | [
"DDInter1297",
"DDInter165"
] | Niraparib | Baricitinib | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Major | 2 | [
[
[
738,
25,
1259
]
],
[
[
738,
63,
1274
],
[
1274,
24,
1259
]
],
[
[
738,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
738,
63,
384
],
[
384,
... | [
[
[
"Niraparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbipro... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Baricitinib
Niraparib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Baricitinib
Niraparib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib |
DB00432 | DB01610 | 1,083 | 248 | [
"DDInter1868",
"DDInter1912"
] | Trifluridine | Valganciclovir | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1083,
24,
248
]
],
[
[
1083,
24,
563
],
[
563,
1,
248
]
],
[
[
1083,
54,
19128
],
[
19128,
15,
248
]
],
[
[
1083,
21,
28719
],
[
28719... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Trifluridine (Compound) is included by Nucleoside Analog (Pharmacologic Class) and Nucleoside Analog (Pharmacologic Class) includes Valganciclovir (Compound)
Trifluridine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Valganciclovir (Compound)
Trifluridine (Compound) resembles Pentostatin (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Trifluridine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Trifluridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir |
DB00196 | DB01045 | 600 | 463 | [
"DDInter743",
"DDInter1590"
] | Fluconazole | Rifampicin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Major | 2 | [
[
[
600,
25,
463
]
],
[
[
600,
24,
690
],
[
690,
40,
463
]
],
[
[
600,
6,
10215
],
[
10215,
45,
463
]
],
[
[
600,
24,
1264
],
[
1264,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
"Rifabutin... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Fluconazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rifampicin (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Fluconazole may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Rifampicin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin |
DB00350 | DB01068 | 1,214 | 1,565 | [
"DDInter1226",
"DDInter411"
] | Minoxidil | Clonazepam | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately, however, like most benzodiazepines, clonazepam use has also been associated with recreational use and drug abuse.[FDA Label][L5572,F3763,F3787,F3796] | Moderate | 1 | [
[
[
1214,
24,
1565
]
],
[
[
1214,
24,
1382
],
[
1382,
1,
1565
]
],
[
[
1214,
24,
1216
],
[
1216,
40,
1565
]
],
[
[
1214,
63,
905
],
[
905,... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Clonazepam (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Clonazepam (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Clonazepam (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Clonazepam
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Midazolam and Midazolam (Compound) resembles Diazepam (Compound) and Diazepam (Compound) resembles Clonazepam (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Oxazepam and Oxazepam (Compound) resembles Cloxazolam (Compound) and Cloxazolam (Compound) resembles Clonazepam (Compound) |
DB00225 | DB00489 | 457 | 17 | [
"DDInter794",
"DDInter1704"
] | Gadodiamide | Sotalol | Gadodiamide is a linear, non-ionic gadolinium-based contrast agent (GBCA) that is used in magnetic resonance imaging (MRI) procedures to assist in the visualization of blood vessels.[A263086,A263091] GBCAs constitute the largest group of MR agents, and they are thought to be safer than nonionic iodinated contrast agents. Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side effects. | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Moderate | 1 | [
[
[
457,
24,
17
]
],
[
[
457,
24,
88
],
[
88,
40,
17
]
],
[
[
457,
21,
28719
],
[
28719,
60,
17
]
],
[
[
457,
40,
1431
],
[
1431,
63... | [
[
[
"Gadodiamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Gadodiamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
... | Gadodiamide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Gadodiamide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sotalol (Compound)
Gadodiamide (Compound) resembles Gadopentetic acid (Compound) and Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Gadodiamide (Compound) resembles Gadoxetic acid (Compound) and Gadoxetic acid may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Gadodiamide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Atenolol (Compound) and Atenolol (Compound) resembles Sotalol (Compound)
Gadodiamide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Atenolol (Compound) and Atenolol (Compound) resembles Sotalol (Compound)
Gadodiamide (Compound) causes Vasodilation procedure (Side Effect) and Vasodilation procedure (Side Effect) is caused by Gadopentetic acid (Compound) and Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Gadodiamide (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Sucralfate (Compound) and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Sotalol
Gadodiamide (Compound) causes Coordination abnormal (Side Effect) and Coordination abnormal (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sotalol |
DB00987 | DB06168 | 1,224 | 1,531 | [
"DDInter460",
"DDInter281"
] | Cytarabine | Canakinumab | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. | Moderate | 1 | [
[
[
1224,
24,
1531
]
],
[
[
1224,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
1224,
63,
377
],
[
377,
24,
1531
]
],
[
[
1224,
24,
1270
],
[
1270... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine (Compound) resembles Fludarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine (Compound) resembles Clofarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Cytarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Cytarabine (Compound) resembles Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab |
DB01244 | DB06603 | 762 | 39 | [
"DDInter192",
"DDInter1387"
] | Bepridil | Panobinostat | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
762,
25,
39
]
],
[
[
762,
62,
112
],
[
112,
23,
39
]
],
[
[
762,
63,
455
],
[
455,
24,
39
]
],
[
[
762,
24,
578
],
[
578,
63,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bepridil may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Bepridil may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Bepridil may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Panobinostat
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Panobinostat
Bepridil (Compound) resembles Dextropropoxyphene (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Panobinostat
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Panobinostat |
DB00889 | DB12887 | 1,133 | 1,598 | [
"DDInter840",
"DDInter1750"
] | Granisetron | Tazemetostat | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1133,
24,
1598
]
],
[
[
1133,
24,
594
],
[
594,
24,
1598
]
],
[
[
1133,
25,
985
],
[
985,
24,
1598
]
],
[
[
1133,
63,
888
],
[
888,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Tazemetostat
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Tazemetostat
Granisetron may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Tazemetostat |
DB06723 | DB12147 | 115 | 241 | [
"DDInter58",
"DDInter661"
] | Aluminum hydroxide | Erdafitinib | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy [L5956, L5959]. Erdafitinib is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to a patient's specific genetic mutation.[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to treat such a prevalent medical condition. | Major | 2 | [
[
[
115,
25,
241
]
],
[
[
115,
63,
478
],
[
478,
24,
241
]
],
[
[
115,
62,
1220
],
[
1220,
25,
241
]
],
[
[
115,
64,
1196
],
[
1196,
... | [
[
[
"Aluminum hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Erdafitinib
Aluminum hydroxide may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercalciferol may lead to a major life threatening interaction when taken with Erdafitinib
Aluminum hydroxide may lead to a major life threatening interaction when taken with Calcium citrate and Calcium citrate may lead to a major life threatening interaction when taken with Erdafitinib
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Calcifediol and Calcifediol may lead to a major life threatening interaction when taken with Erdafitinib
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Erdafitinib
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib |
DB10795 | DB11988 | 221 | 270 | [
"DDInter1486",
"DDInter1321"
] | Poliovirus type 1 antigen (formaldehyde inactivated) | Ocrelizumab | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS.[A18875,A251745] MS is a chronic, inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and a significantly reduced quality of life. Most patients with MS experience episodes of relapses with worsening function, followed by recovery periods or remissions. Primary progressive multiple sclerosis (PPMS) accounts for 10-15% of the overall population of patients with MS, and leads to the gradual worsening of neurologic disability from symptom onset, often without early relapses or remissions . Developed by Genentech/Roche, ocrelizumab was approved by the FDA in March 2017 under the market name Ocrevus for intravenous injection. It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a]. In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and MRI progression rates compared to placebo. | Moderate | 1 | [
[
[
221,
24,
270
]
],
[
[
221,
63,
134
],
[
134,
24,
270
]
],
[
[
221,
24,
1019
],
[
1019,
24,
270
]
],
[
[
221,
24,
398
],
[
398,
6... | [
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction th... | Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab and Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab and Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab |
DB00911 | DB15965 | 458 | 1,330 | [
"DDInter1811",
"DDInter1270"
] | Tinidazole | Naxitamab | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor. | Moderate | 1 | [
[
[
458,
24,
1330
]
],
[
[
458,
24,
14
],
[
14,
24,
1330
]
],
[
[
458,
63,
10
],
[
10,
24,
1330
]
],
[
[
458,
40,
112
],
[
112,
24,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab |
DB01394 | DB09570 | 1,554 | 1,480 | [
"DDInter431",
"DDInter1002"
] | Colchicine | Ixazomib | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions. | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
1554,
24,
1480
]
],
[
[
1554,
63,
268
],
[
268,
24,
1480
]
],
[
[
1554,
24,
148
],
[
148,
63,
1480
]
],
[
[
1554,
24,
98
],
[
98,
... | [
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Colchicine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],... | Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Colchicine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Colchicine may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ixazomib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ixazomib
Colchicine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ixazomib
Colchicine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Ixazomib |
DB00836 | DB00872 | 543 | 1,080 | [
"DDInter1088",
"DDInter438"
] | Loperamide | Conivaptan | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Major | 2 | [
[
[
543,
25,
1080
]
],
[
[
543,
24,
165
],
[
165,
40,
1080
]
],
[
[
543,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
543,
21,
28646
],
[
28646,
... | [
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
],
[
"Tolvaptan",... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Conivaptan (Compound)
Loperamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Loperamide (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Conivaptan (Compound)
Loperamide may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Conivaptan
Loperamide may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Conivaptan
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction when taken with Conivaptan |
DB00631 | DB00738 | 372 | 485 | [
"DDInter405",
"DDInter1420"
] | Clofarabine | Pentamidine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
372,
24,
485
]
],
[
[
372,
24,
1423
],
[
1423,
1,
485
]
],
[
[
372,
7,
5295
],
[
5295,
46,
485
]
],
[
[
372,
7,
4071
],
[
4071,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
],
[... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ospemifene and Ospemifene (Compound) resembles Pentamidine (Compound)
Clofarabine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is upregulated by Pentamidine (Compound)
Clofarabine (Compound) upregulates PNP (Gene) and PNP (Gene) is downregulated by Pentamidine (Compound)
Clofarabine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Pentamidine (Compound)
Clofarabine (Compound) causes Necrosis (Side Effect) and Necrosis (Side Effect) is caused by Pentamidine (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine |
DB00074 | DB14409 | 1,309 | 1,129 | [
"DDInter166",
"DDInter867"
] | Basiliximab | Human adenovirus e serotype 4 strain cl-68578 antigen | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1309,
24,
1129
]
],
[
[
1309,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1309,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1309,
63,
1184
],
[
11... | [
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Basiliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Basiliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Basiliximab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB00357 | DB08895 | 1,051 | 976 | [
"DDInter71",
"DDInter1825"
] | Aminoglutethimide | Tofacitinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Moderate | 1 | [
[
[
1051,
24,
976
]
],
[
[
1051,
24,
307
],
[
307,
23,
976
]
],
[
[
1051,
24,
214
],
[
214,
63,
976
]
],
[
[
1051,
24,
723
],
[
723,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Tofacitinib |
DB00812 | DB12015 | 998 | 1,033 | [
"DDInter1451",
"DDInter53"
] | Phenylbutazone | Alpelisib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822) | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
998,
24,
1033
]
],
[
[
998,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
998,
40,
576
],
[
576,
24,
1033
]
],
[
[
998,
24,
738
],
[
738,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Phenylbutazone (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Phenylbutazone may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB01234 | DB15035 | 1,220 | 503 | [
"DDInter513",
"DDInter1959"
] | Dexamethasone | Zanubrutinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
1220,
25,
503
]
],
[
[
1220,
24,
868
],
[
868,
24,
503
]
],
[
[
1220,
63,
1324
],
[
1324,
24,
503
]
],
[
[
1220,
25,
1362
],
[
1362,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"V... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Dexamethasone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Dexamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Zanubrutinib
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Zanubrutinib
Dexamethasone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Zanubrutinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Zanubrutinib
Dexamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Zanubrutinib |
DB00294 | DB00673 | 1,336 | 723 | [
"DDInter701",
"DDInter112"
] | Etonogestrel | Aprepitant | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Moderate | 1 | [
[
[
1336,
24,
723
]
],
[
[
1336,
6,
8374
],
[
8374,
45,
723
]
],
[
[
1336,
21,
28847
],
[
28847,
60,
723
]
],
[
[
1336,
25,
1101
],
[
1101... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Etonogestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Etonogestrel (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Aprepitant (Compound)
Etonogestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Etonogestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Etonogestrel may lead to a major life threatening interaction when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Etonogestrel (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Etonogestrel (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.